Allergy DN II Interactions
There are 393 drugs known to interact with Allergy DN II (chlorpheniramine / methscopolamine), along with 21 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, 10 are major, 365 are moderate, and 18 are minor.
- View all 393 medications that may interact with Allergy DN II
- View Allergy DN II alcohol/food interactions (2)
- View Allergy DN II disease interactions (21)
Most frequently checked interactions
View interaction reports for Allergy DN II (chlorpheniramine / methscopolamine) and the medicines listed below.
- amlodipine
- clindamycin
- cranberry
- Inlyta (axitinib)
- Keytruda (pembrolizumab)
- levothyroxine
- loratadine
- Metoprolol Tartrate (metoprolol)
- sumatriptan
- Vitamin C (ascorbic acid)
Allergy DN II alcohol/food interactions
There are 2 alcohol/food interactions with Allergy DN II (chlorpheniramine / methscopolamine).
Allergy DN II disease interactions
There are 21 disease interactions with Allergy DN II (chlorpheniramine / methscopolamine) which include:
- autonomic neuropathy
- GI obstruction
- glaucoma
- obstructive uropathy
- reactive airway diseases
- myasthenia gravis
- infectious diarrhea
- cardiac disease
- tachycardia
- anticholinergic effects
- asthma/COPD
- cardiovascular
- renal/liver disease
- coronary artery disease
- gastric ulcer
- gastroesophageal reflux
- ulcerative colitis
- hypertension
- hyperthyroidism
- diarrhea
- fever
More about Allergy DN II (chlorpheniramine / methscopolamine)
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.